Arcturus Therapeutics Holdings/$ARCT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Arcturus Therapeutics Holdings
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.
Ticker
$ARCT
Sector
Primary listing
Employees
109
Headquarters
Website
ARCT Metrics
BasicAdvanced
$182M
-
-$2.40
2.49
-
Price and volume
Market cap
$182M
Beta
2.49
52-week high
$24.17
52-week low
$5.85
Average daily volume
479K
Financial strength
Current ratio
6.637
Quick ratio
6.5
Long term debt to equity
9.713
Total debt to equity
11.682
Interest coverage (TTM)
-8,473.33%
Profitability
EBITDA (TTM)
-73.235
Gross margin (TTM)
-36.79%
Net profit margin (TTM)
-80.19%
Operating margin (TTM)
-92.96%
Revenue per employee (TTM)
$750,000
Management effectiveness
Return on assets (TTM)
-15.49%
Return on equity (TTM)
-28.92%
Valuation
Price to revenue (TTM)
2.133
Price to book
0.85
Price to tangible book (TTM)
0.85
Price to free cash flow (TTM)
-2.349
Free cash flow yield (TTM)
-42.57%
Free cash flow per share (TTM)
-2.72
Growth
Revenue change (TTM)
-46.14%
Earnings per share change (TTM)
-19.87%
3-year revenue growth (CAGR)
-26.43%
10-year revenue growth (CAGR)
29.60%
3-year earnings per share growth (CAGR)
90.04%
10-year earnings per share growth (CAGR)
9.80%
What the Analysts think about ARCT
Analyst ratings (Buy, Hold, Sell) for Arcturus Therapeutics Holdings stock.
ARCT Financial Performance
Revenues and expenses
ARCT Earnings Performance
Company profitability
ARCT News
AllArticlesVideos
Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Pipeline Progress
Business Wire·2 weeks ago
Arcturus Therapeutics to Report Fourth Quarter and Fiscal Year 2025 Financial Results and Provide Corporate Update on March 3, 2026
Business Wire·4 weeks ago
Arcturus Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Arcturus Therapeutics Holdings stock?
Arcturus Therapeutics Holdings (ARCT) has a market cap of $182M as of March 18, 2026.
What is the P/E ratio for Arcturus Therapeutics Holdings stock?
The price to earnings (P/E) ratio for Arcturus Therapeutics Holdings (ARCT) stock is 0 as of March 18, 2026.
Does Arcturus Therapeutics Holdings stock pay dividends?
No, Arcturus Therapeutics Holdings (ARCT) stock does not pay dividends to its shareholders as of March 18, 2026.
When is the next Arcturus Therapeutics Holdings dividend payment date?
Arcturus Therapeutics Holdings (ARCT) stock does not pay dividends to its shareholders.
What is the beta indicator for Arcturus Therapeutics Holdings?
Arcturus Therapeutics Holdings (ARCT) has a beta rating of 2.49. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.